Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title> <jats:p> <jats:italic>Bacillus subtilis</jats:italic> spores are being used for oral bacteriotherapy and bacterioprophylaxis of gastrointestinal disorders in both humans and animals. Since <jats:italic>B. subtilis</jats:italic> is an aerobic saprophyte, how spores may benefit the gut microbiota is an intriguing question, since other probiotics such as <jats:italic>Lactobacillus</jats:italic> spp. which colonize the gut are anerobes. As a first step in understanding the potential effects of ingesting spores, we have characterized five commercial products. An extensive biochemical, physiological, and phylogenetic analysis has revealed that four of these products are mislabeled. Moreover, four of these products showed high levels of antibiotic resistance.</jats:p>

Original publication

DOI

10.1128/aem.66.12.5241-5247.2000

Type

Journal article

Journal

Applied and Environmental Microbiology

Publisher

American Society for Microbiology

Publication Date

01/12/2000

Volume

66

Pages

5241 - 5247